Skip to main content

Table 4 Results of sensitivity analysis

From: Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study

Cost/patient

Interferon-β

Glatiramer acetate

Cost difference (interferon-β versus glatiramer acetate)

Base case

7,078.02€

4,671.31€

2,406.71€

When considering no concomitant/spasticity treatment

6,225.96€

4,335.94€

1,890.02€

When applying an annual discount rate of 3 %

6,871.86€

4,535.25€

2,336.61€

When applying an annual discount rate of 5 %

6,740.97€

4,448.87€

2,292.10€

  1. The cost analyses are expressed in 2014 euros (€)